Research
What makes a label statement count as being on the label
Federal drug labeling rules are not only about what a label says. They also set how visible a required statement has to be, what language it has to be in, and where it may sit when the container is too small to hold it.
Printed and present is not the same as legally borne
Most writing about drug labels asks what has to appear on one. There is a second question underneath it, and it decides whether the first one was answered.
The misbranding statute has a paragraph devoted to it. A drug is misbranded if a required word, statement or other information is not prominently placed on the label with the required conspicuousness. The statute measures that conspicuousness against the other words, statements, designs or devices in the labeling. It also requires terms likely to be read and understood by the ordinary individual under customary conditions of purchase and use.
Read that slowly and it is a comparison, not a measurement. The test is not a type size. It is how the required statement sits beside everything a designer chose to put around it.
That is a useful thing to know when looking at a product photograph. A brand name at the top of a vial and a required statement crushed into the last line of the panel is exactly the arrangement the paragraph is written about.
Six named ways a statement stops counting
The implementing regulation does something regulations rarely do. It lists the failures by name, and says the list is not exhaustive.
A required statement may lack prominence because it does not appear on the part or panel of the label that is presented or displayed under customary conditions of purchase. Or because it does not appear on two or more parts or panels, each of which has room for it and each of which is likely to be the one displayed.
It may fail because the label does not extend over the area of the container available for it, so there is not enough label to place the statement prominently.
It may fail because label space was used for a word, statement, design or device that no rule required. It may fail because label space was used to give materially greater conspicuousness to something else.
And it may fail because of smallness or style of type, insufficient background contrast, obscuring designs or vignettes, or crowding with other written, printed or graphic matter.
Four of those six are about design decisions rather than printing errors. That is the part worth carrying away.
The rule that stops a company writing its own excuse
Labeling rules contain exemptions that depend on a shortage of label space. A small container genuinely cannot hold everything, and the regulations acknowledge that in several places.
The prominence regulation then closes the obvious loop. No exemption depending on insufficiency of label space applies if that insufficiency was caused by three named things.
The first is the use of label space for any word, statement, design or device that no rule required. The second is the use of label space to give greater conspicuousness to something than the statute requires. The third is the use of label space for any representation in a foreign language.
So a company cannot fill a panel with branding, run out of room, and then claim the room was never there. The excuse has to be the container, not the layout.
The language rule, and the second rule it drags behind it
All words, statements and other information required to appear on a label or labeling have to appear in English. There is a stated exception for articles distributed solely in Puerto Rico or in a territory where the predominant language is not English.
Then comes a clause people do not expect. If the label contains any representation in a foreign language, all the required statements have to appear on the label in that foreign language as well.
The same applies one level out. If the labeling contains a representation in a foreign language, the required statements have to appear in the labeling in that language too.
A separate regulation shows what that means in practice. For prescription drugs labeled in Spanish for Puerto Rico, it fixes the Spanish version of one statement whose English wording is set by statute, and prints the words the label must bear.
The reason it exists is stated in the regulation itself. That statement could be translated in many ways, from literal to loose, and its statutory nature requires the translation to carry the meaning without dilution.
Where the date goes, and what the number is supposed to reach
Two items on a drug package have their own placement rules, and both are items a buyer can check.
When an expiration date is required, it has to appear on the immediate container and also on the outer package, if there is one, unless it is easily legible through that outer package. Where single-dose containers are packed in individual cartons, the date may appear on the carton instead of the container.
That is a rule about a box you are holding. If the vial is inside a carton and the carton is opaque, the date is supposed to be in both places.
The lot number has a short regulation of its own, and its second sentence is the sharp one. The number on the label should be capable of yielding the complete manufacturing history of the package, and an incorrect lot number may be regarded as causing the article to be misbranded.
Two ideas sit inside that. A lot number is meant to lead somewhere, and a wrong one is not a typographical matter in the regulation's own view.
What the package says it holds, and the word "minimum"
The label of a prescription drug in package form has to bear a declaration of the net quantity of contents. That declaration has to appear as a distinct item on the label, not folded into a sentence about something else.
It has to express, with prominence and conspicuousness, the number of the largest whole unit in the package, with any remainder expressed in fractions or in the next smaller whole unit.
Then a paragraph about vials that this market should know. In the case of a liquid drug in ampules or vials intended for injection, the declaration is considered to express the minimum quantity. The variation above the stated measure follows the excess-volume rules in the official compendia.
For a solid drug in ampules or vials the declaration is considered to express the accurate net weight, with variations limited by the same books.
A separate regulation adds the statement of identity, which has to be one of the principal features of the label and to be given in terms of the established name. For a prescription mixture with no established name, listing the quantitative ingredient information satisfies the requirement instead.
When the container is too small, the rules already know
A vial is a small object, and the labeling regulations have a worked answer rather than a shrug.
The prescription-drug labeling regulation carries a proviso for containers too small, or otherwise unable, to accommodate a label with room for everything. It applies where those containers sit inside an outer container from which they are removed for dispensing or use.
In that case several of the required items may instead appear in other labeling on or within the package the drug is dispensed from. One item may be placed on the outer container only. The identifying lot or control number may be on the crimp of the dispensing tube.
So the answer to "how does all of that fit on a vial" is that it often does not, and the regulation redistributes it rather than waiving it. The information is supposed to travel with the package.
That is also why a photograph of a bare vial is weak evidence in both directions. What is missing from the glass may be on the carton, and what is on the carton may be the only copy.
The bar code rule, and the exemption that describes this market
Bar codes on drug packages are required by a regulation with an unusually clear scope paragraph, and the scope is the interesting part here.
The requirement reaches manufacturers, repackers, relabelers and private label distributors of a human prescription or over-the-counter drug product, unless they are exempt from the registration and drug listing requirements in section 510 of the Act.
Then a carve-out that lands squarely on a mail-order market. The bar code requirement does not apply to prescription drugs sold by a manufacturer, repacker, relabeler or private label distributor directly to patients. Versions of the same product sold to or used in hospitals are still covered.
The regulation also lists specific exclusions, including drug samples, medical gases, radiopharmaceuticals and allergenic extracts. Where the requirement does apply, the code has to carry at least the national drug code number, sit in enough blank space to scan, and remain intact under normal conditions of use.
The reason to know this is narrow and useful. A vial with no bar code is not evidence of anything irregular, because two separate provisions in the rule may already have released it.
Why most of this stops before the vial you are handed
Everything above governs a label on a drug moving in commerce. A drug dispensed by filling or refilling a prescription is exempt from the misbranding section, with a short list of exceptions, on condition its own label bears five stated items.
The prominence paragraph is not on that list of exceptions. Neither is the paragraph requiring an accurate statement of the quantity of contents. What is preserved is the paragraph on false or misleading labeling, two clauses about imitation and about selling under another drug's name, and the packaging requirements of three further paragraphs.
There is a detail in that list worth reading carefully. As the statute is printed today, two of the paragraphs it preserves are marked repealed, by a public law dated in 1997.
None of that is a statement about whether any particular label complies with anything. It is a statement about which rules are addressed to whom.
The practical effect is that the design standard on this page is a manufacturer-side standard. The dispensed label answers to a truth standard instead, which sets no type size and prescribes no layout.
One more scope line, because the phrase turns up in guidance about injectable labels. The regulation defining a principal display panel in this part defines it as it applies to over-the-counter drugs in package form.
What is worth looking at on a label you already have
None of this decides whether a product is good. It gives a short list of observations that are cheap to make and hard to fake.
Is every required item on the panel that faces you, or is some of it on a side you would have to turn the container to read? Is the type small enough that it competes with the branding around it?
Is the expiration date on the vial itself, and also on the carton, or legible through it? Is there a lot number, and does it match the number on any certificate supplied with the order?
Is there a statement of what the drug is, given in a real drug name rather than only a product nickname? Is the quantity in the container stated as a distinct item?
And if a carton came with the vial, keep it. Under the small-container rule, the carton may be carrying the only copy of several things.
Key takeaways
- A required statement can be printed on a label and still fail the rule, because the statutory test compares it with everything around it.
- The regulation names six ways prominence fails, and four of the six are design decisions rather than printing errors.
- No exemption for insufficient label space applies where the shortage was created by unrequired matter, by emphasizing something else, or by a foreign-language representation.
- One representation in a foreign language pulls every required statement into that language as well.
- An expiration date belongs on the immediate container and the outer package, unless it is easily legible through the package.
- An incorrect lot number may be regarded as causing the article to be misbranded, which is stronger than treating it as a typographical slip.
- For a liquid in vials intended for injection, the declared quantity is treated as the minimum, not as an exact figure.
- A drug dispensed on a prescription is exempt from most of the misbranding section, and the prominence paragraph is not one of the exceptions.
Frequently asked questions
Can a required statement be on a drug label and still not satisfy the rule?
Yes, and the regulation lists six ways that happens. The statement may not be on the panel that is displayed under customary conditions of purchase. The label may not extend across the space available on the container. Space may have been used for material no rule required, or used to give something else materially greater conspicuousness. Or the type may be too small or in a style, contrast, design or crowding that defeats it. The statute's own test is comparative: prominence measured against the other words, designs and devices around it.
A vial is tiny. How is a company supposed to fit everything on it?
It often is not, and the prescription-drug labeling regulation says what happens then. That happens where a container is too small to hold a label with room for the required information. The container also has to sit inside an outer container it is removed from for dispensing or use. Several items may then appear in other labeling on or within that package instead. One item may go on the outer container only, and the lot or control number may go on the crimp of a dispensing tube. The information is redistributed rather than dropped, which is why the carton matters.
Why do some labels repeat everything in a second language?
Because of a clause most people never read. Required statements have to appear in English, with a stated exception for articles distributed solely in Puerto Rico or a territory where the predominant language is not English. If a label carries any representation in a foreign language, then every required statement has to appear on that label in that language too. The same applies to labeling. A single marketing line in another language pulls the whole required set along with it.
Where is the expiration date supposed to appear?
When an expiration date is required, the regulation puts it on the immediate container and also on the outer package, if there is one, unless it is easily legible through that outer package. There is one stated alternative: where single-dose containers are packed in individual cartons, the date may appear on the individual carton instead of the container itself. So a date on the box and nothing on the vial is a pattern the rule anticipates only in that case.
Does a wrong lot number matter, or is it just a typo?
The regulation on control numbers is two sentences and the second answers this directly. The lot number on the label of a drug should be capable of yielding the complete manufacturing history of the package. An incorrect lot number may be regarded as causing the article to be misbranded. That is a stronger position than most people assume. The number is treated as an index into records, so a number that leads nowhere is a different thing from a number that is simply printed.
My vial has no bar code. Is something wrong?
Not on its own. The bar code regulation reaches manufacturers, repackers, relabelers and private label distributors, and it does not reach anyone exempt from federal establishment registration and drug listing. It also carves out prescription drugs sold by those parties directly to patients, while keeping versions of the same product sold to or used in hospitals inside the rule. Two separate provisions can release the same package, so an absent bar code is not by itself a signal about anything.
Do these design rules apply to the label a pharmacy puts on my vial?
Mostly no, and the statute is explicit about it. A drug dispensed by filling or refilling a prescription is exempt from the misbranding section except for a listed few paragraphs, on condition its label bears five stated items. The prominence paragraph is not among the exceptions, and neither is the paragraph on stating the quantity of contents. What continues to apply is the requirement that labeling not be false or misleading in any particular, which sets a standard of truth rather than a standard of layout.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- United States Code Title 21, Section 352, Misbranded drugs and devices, subsection (c) on prominence of information on the label, subsection (b) on package form and contents of label, and the paragraphs (k) and (l) marked repealed by Public Law 105-115, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
- United States Code Title 21, Section 353(b)(2), exempting a drug dispensed by filling or refilling a prescription from section 352 except the paragraphs it lists, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
- Title 21 Code of Federal Regulations Section 201.15, Drugs; prominence of required label statements, read in full including the six failures listed at paragraph (a), the three causes at paragraph (b) that defeat any label-space exemption, and the English and foreign-language requirements at paragraph (c) — Electronic Code of Federal Regulations, Office of the Federal Register, February 1976
- Title 21 Code of Federal Regulations Section 201.16, Drugs; Spanish-language version of certain required statements — Electronic Code of Federal Regulations, Office of the Federal Register, February 2002
- Title 21 Code of Federal Regulations Section 201.17, Drugs; location of expiration date — Electronic Code of Federal Regulations, Office of the Federal Register, September 1978
- Title 21 Code of Federal Regulations Section 201.18, Drugs; significance of control numbers, carrying no amendment bracket of its own and taking its printed date from the source note for part 201 — Electronic Code of Federal Regulations, Office of the Federal Register, March 1975
- Title 21 Code of Federal Regulations Section 201.25, Bar code label requirements, including the scope paragraph and the carve-out at paragraph (b)(1)(ii) for prescription drugs sold directly to patients — Electronic Code of Federal Regulations, Office of the Federal Register, August 2016
- Title 21 Code of Federal Regulations Section 201.50, Statement of identity, requiring it as one of the principal features of the label and in terms of the established name — Electronic Code of Federal Regulations, Office of the Federal Register, May 1998
- Title 21 Code of Federal Regulations Section 201.51, Declaration of net quantity of contents, including paragraph (d) requiring it as a distinct item, paragraph (f) on prominence and conspicuousness, and paragraph (g) treating the declaration on an injectable liquid in ampules or vials as the minimum quantity — Electronic Code of Federal Regulations, Office of the Federal Register, June 2024
- Title 21 Code of Federal Regulations Section 201.100, Prescription drugs for human use, paragraph (b)(7) and its proviso permitting required information to be redistributed where a container is too small to accommodate a label bearing all of it — Electronic Code of Federal Regulations, Office of the Federal Register, January 2006
- Title 21 Code of Federal Regulations Section 201.60, Principal display panel, defining the term as it applies to over-the-counter drugs in package form and as used in that part — Electronic Code of Federal Regulations, Office of the Federal Register, March 1975